Patients taking COMP360 psilocybin with concomitant SSRIs showed comparable treatment outcomes to patients withdrawn from their SSRI therapy in COMPASS’s phase IIb trial All patients tolerated COMP360 psilocybin therapy well London, UK – 13 December 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based…


Previous articlePsychedelic Research Bulletin: November 2021
Next articleLobe Sciences Announces That Its Shares Will Trade on the OTCQB(R) Market in the United States